|Bid||33.80 x 10000|
|Ask||34.05 x 3000|
|Day's Range||33.81 - 34.19|
|52 Week Range||25.55 - 35.04|
|PE Ratio (TTM)||25.36|
|Dividend & Yield||1.90 (5.53%)|
|1y Target Est||N/A|
AstraZeneca is voluntarily recalling one lot of physician sample bottles of Brilinta — a blood-thinning drug prescribed to prevent stroke, heart attack and other heart problems — as a precautionary measure. The London-based pharmaceutical company, which has its U.S. headquarters in Wilmington, said the voluntary recall follows a report that a professional sample bottle containing eight, 90 milligram tablets of Brilinta also contained another medicine, Zurampic tablets, also manufactured by AstraZeneca (AZN).
Combined sales for Januvia and Janumet were ~$1.3 billion for 1Q17, a ~5.0% fall from $1.4 billion in 1Q16.
AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.